vs
Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
Cytek Biosciences, Inc. is the larger business by last-quarter revenue ($62.1M vs $57.3M, roughly 1.1× RHYTHM PHARMACEUTICALS, INC.). Cytek Biosciences, Inc. runs the higher net margin — -70.9% vs -83.0%, a 12.0% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs 8.1%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 17.7%).
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
CTKB vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $62.1M | $57.3M |
| Net Profit | $-44.1M | $-47.5M |
| Gross Margin | 52.9% | 91.6% |
| Operating Margin | -9.0% | -82.2% |
| Net Margin | -70.9% | -83.0% |
| Revenue YoY | 8.1% | 36.9% |
| Net Profit YoY | -557.1% | -9.6% |
| EPS (diluted) | — | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $62.1M | $57.3M | ||
| Q3 25 | $52.3M | $51.3M | ||
| Q2 25 | $45.6M | $48.5M | ||
| Q1 25 | $41.5M | $32.7M | ||
| Q4 24 | $57.5M | $41.8M | ||
| Q3 24 | $51.5M | $33.3M | ||
| Q2 24 | $46.6M | $29.1M | ||
| Q1 24 | $44.9M | $26.0M |
| Q4 25 | $-44.1M | $-47.5M | ||
| Q3 25 | $-5.5M | $-52.9M | ||
| Q2 25 | $-5.6M | $-46.6M | ||
| Q1 25 | $-11.4M | $-49.5M | ||
| Q4 24 | $9.6M | $-43.3M | ||
| Q3 24 | $941.0K | $-43.6M | ||
| Q2 24 | $-10.4M | $-32.3M | ||
| Q1 24 | $-6.2M | $-141.4M |
| Q4 25 | 52.9% | 91.6% | ||
| Q3 25 | 52.7% | 89.3% | ||
| Q2 25 | 52.3% | 88.6% | ||
| Q1 25 | 48.6% | 88.8% | ||
| Q4 24 | 58.5% | 90.9% | ||
| Q3 24 | 56.3% | 88.5% | ||
| Q2 24 | 54.6% | 89.9% | ||
| Q1 24 | 51.3% | 89.2% |
| Q4 25 | -9.0% | -82.2% | ||
| Q3 25 | -17.6% | -102.6% | ||
| Q2 25 | -23.3% | -93.4% | ||
| Q1 25 | -36.1% | -143.7% | ||
| Q4 24 | 5.2% | -98.6% | ||
| Q3 24 | -8.2% | -132.0% | ||
| Q2 24 | -18.3% | -139.2% | ||
| Q1 24 | -23.9% | -538.7% |
| Q4 25 | -70.9% | -83.0% | ||
| Q3 25 | -10.5% | -103.1% | ||
| Q2 25 | -12.2% | -96.1% | ||
| Q1 25 | -27.5% | -151.4% | ||
| Q4 24 | 16.8% | -103.6% | ||
| Q3 24 | 1.8% | -131.2% | ||
| Q2 24 | -22.4% | -110.9% | ||
| Q1 24 | -13.8% | -544.4% |
| Q4 25 | — | $-0.73 | ||
| Q3 25 | — | $-0.82 | ||
| Q2 25 | — | $-0.75 | ||
| Q1 25 | — | $-0.81 | ||
| Q4 24 | — | $-0.71 | ||
| Q3 24 | — | $-0.73 | ||
| Q2 24 | — | $-0.55 | ||
| Q1 24 | — | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $90.9M | $388.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $341.7M | $139.1M |
| Total Assets | $461.5M | $480.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $90.9M | $388.9M | ||
| Q3 25 | $93.3M | $416.1M | ||
| Q2 25 | $75.5M | $291.0M | ||
| Q1 25 | $95.3M | $314.5M | ||
| Q4 24 | $98.7M | $320.6M | ||
| Q3 24 | $162.3M | $298.4M | ||
| Q2 24 | $177.9M | $319.1M | ||
| Q1 24 | $168.8M | $201.2M |
| Q4 25 | $341.7M | $139.1M | ||
| Q3 25 | $378.6M | $148.8M | ||
| Q2 25 | $377.6M | $-11.9M | ||
| Q1 25 | $379.6M | $18.9M | ||
| Q4 24 | $395.7M | $21.7M | ||
| Q3 24 | $385.5M | $11.2M | ||
| Q2 24 | $389.1M | $39.3M | ||
| Q1 24 | $392.6M | $61.6M |
| Q4 25 | $461.5M | $480.2M | ||
| Q3 25 | $494.9M | $506.9M | ||
| Q2 25 | $493.3M | $372.7M | ||
| Q1 25 | $482.6M | $386.7M | ||
| Q4 24 | $499.5M | $392.3M | ||
| Q3 24 | $491.2M | $363.6M | ||
| Q2 24 | $483.7M | $381.8M | ||
| Q1 24 | $492.1M | $258.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-771.0K | $-25.4M |
| Free Cash FlowOCF − Capex | $-1.8M | — |
| FCF MarginFCF / Revenue | -2.9% | — |
| Capex IntensityCapex / Revenue | 1.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-8.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-771.0K | $-25.4M | ||
| Q3 25 | $-3.9M | $-26.6M | ||
| Q2 25 | $108.0K | $-23.3M | ||
| Q1 25 | $-125.0K | $-40.4M | ||
| Q4 24 | $2.0M | $-18.8M | ||
| Q3 24 | $13.2M | $-25.2M | ||
| Q2 24 | $6.2M | $-29.1M | ||
| Q1 24 | $4.0M | $-40.7M |
| Q4 25 | $-1.8M | — | ||
| Q3 25 | $-4.6M | — | ||
| Q2 25 | $-1.5M | — | ||
| Q1 25 | $-974.0K | — | ||
| Q4 24 | $1.1M | — | ||
| Q3 24 | $12.2M | — | ||
| Q2 24 | $5.2M | — | ||
| Q1 24 | $3.4M | — |
| Q4 25 | -2.9% | — | ||
| Q3 25 | -8.7% | — | ||
| Q2 25 | -3.2% | — | ||
| Q1 25 | -2.3% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 23.7% | — | ||
| Q2 24 | 11.0% | — | ||
| Q1 24 | 7.6% | — |
| Q4 25 | 1.6% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 2.0% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 2.0% | — | ||
| Q2 24 | 2.3% | — | ||
| Q1 24 | 1.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | 14.05× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
RYTM
Segment breakdown not available.
